CytomX Therapeutics, Inc. Deferred Revenue
CytomX Therapeutics, Inc. (CTMX) had Deferred Revenue of $301.83 million as of 2018-06-30, per its 10-Q filed 2018-08-08.
Discontinued › Balance Sheet › Liabilities
us-gaap:DeferredRevenue · last filed 2018-08-08
- 2018-06-30: Deferred Revenue $301.83M.
- 2018-03-31: Deferred Revenue $302.04M.
- 2017-12-31: Deferred Revenue $305.26M.
| Period end | Deferred Revenue |
|---|---|
| 2018-06-30 | $301.83M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $302.04M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $305.26M 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |